Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase NA 7Phase 1/2 5Phase 1 4Phase 4 2Phase 3 1

Status

Recruiting 5Completed 5Active not recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 4OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 155Neoplasms 115Colorectal Neoplasms 97Breast Neoplasms 92Pancreatic Neoplasms 80Neoplasm Metastasis 80Leukemia, Myeloid, Acute 79Recurrence 76Melanoma 74Prostatic Neoplasms 73Ovarian Neoplasms 73Multiple Myeloma 66Stomach Neoplasms 59Squamous Cell Carcinoma of Head and Neck 55Lung Neoplasms 55Triple Negative Breast Neoplasms 50Glioblastoma 48Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 42Advanced Solid Tumor 42Lymphoma, Non-Hodgkin 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Advanced Solid Tumors 37Small Cell Lung Carcinoma 35Uterine Cervical Neoplasms 34Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 29

Interventions

Pemetrexed 4sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Meningeal Carcinomatosis × Clear all
NCT07264569 2025-12-04

Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001

Henan Cancer Hospital

Phase 1/2 Recruiting
42 enrolled
CNS

Meningeal Carcinomatosis

NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Guangzhou Medical University

Phase 1/2 Recruiting
34 enrolled
BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

NCT06762080 2025-05-20

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

Guangzhou Medical University

Phase 1/2 Recruiting
36 enrolled
CNS

Meningeal Carcinomatosis

NCT06809517 2025-05-20

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

Guangzhou Medical University

Phase 1/2 Recruiting
34 enrolled
CNS

Meningeal Carcinomatosis

NCT06809530 2025-05-18

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Guangzhou Medical University

Phase 1/2 Recruiting
34 enrolled
CNS

Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡